The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And four other potential targets that could make sense for the beleaguered group.
The beleaguered big pharma is under huge pressure to change minds at Wednesday’s investor event.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.